Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods

To predict the pharmacokinetic/pharmacodynamic (PK/PD) profiles of imigliptin, a novel DPP-4 inhibitor, in first-in-human (FIH) study based on the data from preclinical species. Imigliptin was intravenously and orally administered to rats, dogs, and monkeys to assess their PK/PD properties. DPP-4 ac...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutical sciences 2016-06, Vol.89, p.73-82
Main Authors: Liu, Dongyang, Ma, Xifeng, Liu, Yang, Zhou, Huimin, Shi, Chongtie, Wu, Frank, Jiang, Ji, Hu, Pei
Format: Article
Language:English
Subjects:
Administration, Oral
Animals
Area Under Curve
Dipeptidyl Peptidase 4 - metabolism
Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics
Dipeptidyl-Peptidase IV Inhibitors - pharmacology
Dogs
Female
First-in-human
Haplorhini
Humans
Imidazoles - pharmacokinetics
Imidazoles - pharmacology
Imigliptin
Male
Pharmacodynamics
Pharmacokinetics
Piperidines - pharmacokinetics
Piperidines - pharmacology
Prediction
Pyridines - pharmacokinetics
Pyridines - pharmacology
Rats
Rats, Sprague-Dawley
Sitagliptin Phosphate - pharmacokinetics
Sitagliptin Phosphate - pharmacology
Uracil - analogs & derivatives
Uracil - pharmacokinetics
Uracil - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!